Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Eva Zhang; Thi H O Nguyen; Lilith F Allen; Lukasz Kedzierski; Louise C Rowntree; So Young Chang; Wuji Zhang; Jennifer R Habel; Isabelle J Foo; Tejas Menon; Jeni Mitchell; Rupert W Leong; Katherine Bond; Deborah A Williamson; Katherine Kedzierska; Britt Christensen

doi:10.1136/gutjnl-2022-329136

Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Eva Zhang, Thi H O Nguyen, Lilith F Allen, Lukasz Kedzierski, Louise C Rowntree, So Young Chang, Wuji Zhang, Jennifer R Habel, Isabelle J Foo, Tejas Menon, Jeni Mitchell, Rupert W Leong, Katherine Bond, Deborah A Williamson, Katherine Kedzierska, Britt Christensen

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	712-714
Number of pages	3
Journal	Gut
Volume	73
Issue number	4
DOIs	https://doi.org/10.1136/gutjnl-2022-329136
Publication status	Published - 7 Mar 2024

Keywords

Humans
COVID-19 Vaccines
COVID-19/prevention & control
SARS-CoV-2
T-Lymphocytes
Tumor Necrosis Factor Inhibitors
Antibodies, Viral
Inflammatory Bowel Diseases/drug therapy
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/gutjnl-2022-329136

Cite this

Zhang, E., Nguyen, T. H. O., Allen, L. F., Kedzierski, L., Rowntree, L. C., Chang, S. Y., Zhang, W., Habel, J. R., Foo, I. J., Menon, T., Mitchell, J., Leong, R. W., Bond, K., Williamson, D. A., Kedzierska, K., & Christensen, B. (2024). Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments. Gut, 73(4), 712-714. https://doi.org/10.1136/gutjnl-2022-329136

@article{733944d5c93f4c978f237a210c6c354d,

title = "Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments",

keywords = "Humans, COVID-19 Vaccines, COVID-19/prevention & control, SARS-CoV-2, T-Lymphocytes, Tumor Necrosis Factor Inhibitors, Antibodies, Viral, Inflammatory Bowel Diseases/drug therapy, Vaccination",

author = "Eva Zhang and Nguyen, {Thi H O} and Allen, {Lilith F} and Lukasz Kedzierski and Rowntree, {Louise C} and Chang, {So Young} and Wuji Zhang and Habel, {Jennifer R} and Foo, {Isabelle J} and Tejas Menon and Jeni Mitchell and Leong, {Rupert W} and Katherine Bond and Williamson, {Deborah A} and Katherine Kedzierska and Britt Christensen",

year = "2024",

month = mar,

day = "7",

doi = "10.1136/gutjnl-2022-329136",

language = "English",

volume = "73",

pages = "712--714",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "4",

}

Zhang, E, Nguyen, THO, Allen, LF, Kedzierski, L, Rowntree, LC, Chang, SY, Zhang, W, Habel, JR, Foo, IJ, Menon, T, Mitchell, J, Leong, RW, Bond, K, Williamson, DA, Kedzierska, K & Christensen, B 2024, 'Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments', Gut, vol. 73, no. 4, pp. 712-714. https://doi.org/10.1136/gutjnl-2022-329136

TY - JOUR

T1 - Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

AU - Zhang, Eva

AU - Nguyen, Thi H O

AU - Allen, Lilith F

AU - Kedzierski, Lukasz

AU - Rowntree, Louise C

AU - Chang, So Young

AU - Zhang, Wuji

AU - Habel, Jennifer R

AU - Foo, Isabelle J

AU - Menon, Tejas

AU - Mitchell, Jeni

AU - Leong, Rupert W

AU - Bond, Katherine

AU - Williamson, Deborah A

AU - Kedzierska, Katherine

AU - Christensen, Britt

PY - 2024/3/7

Y1 - 2024/3/7

KW - Humans

KW - COVID-19 Vaccines

KW - COVID-19/prevention & control

KW - SARS-CoV-2

KW - T-Lymphocytes

KW - Tumor Necrosis Factor Inhibitors

KW - Antibodies, Viral

KW - Inflammatory Bowel Diseases/drug therapy

KW - Vaccination

U2 - 10.1136/gutjnl-2022-329136

DO - 10.1136/gutjnl-2022-329136

M3 - Letter

C2 - 36878683

SN - 0017-5749

VL - 73

SP - 712

EP - 714

JO - Gut

JF - Gut

IS - 4

ER -